Enanta Pharmaceuticals Inc

Research Enanta Pharmaceuticals Inc (ENTA) on Bullrun: market cap USD 421.93M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerENTA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 421.93M
• Financial periodFY2025
• RevenueUSD 65.32M
• Revenue growth-3.4%
• Net income-USD 81.89M
• Free cash flow-USD 32.17M

Valuation Snapshot

latest market cap is USD 421.93M.

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses;

Frequently asked questions

What is Enanta Pharmaceuticals Inc's market cap?

Enanta Pharmaceuticals Inc's market capitalization is USD 421.93M.

What does Enanta Pharmaceuticals Inc do?

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV;